Effects of non‐viable<i>Lactobacillus reuteri</i>combining with 14‐day standard triple therapy on<i>Helicobacter pylori</i>eradication: A randomized double‐blind placebo‐controlled trial

Abstract

Supplementation of non-viable L. reuteri DSM17648 with triple therapy did not improve the eradication rate of H. pylori, but it helped to build up a beneficial microbial profile and reduced the frequencies of abdominal distention, diarrhea, and the GSRS score.